Metabolic & Cardiometabolic
statins worsens skeletal-muscle mitochondrial function and CoQ10 status, contributing to myalgia
In plain terms: Do statins damage muscle energy machinery (mitochondria/CoQ10) and cause the muscle aches people report?
Part of: 💊 statins
Statins measurably lower muscle mitochondrial respiration, but CoQ10 depletion is inconsistent and blinded trials show most reported muscle aches are not actually caused by the drug.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
<!-- vault-context --> Norwitz **affirms** this claim. Consensus below reflects independent literature only.
The evidence (11)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Wood 2020 (SAMSON) venue: N Engl J Med · N Engl J Med | RCT | contradicts | high | N-of-1 crossover: 90% of statin-attributed symptom burden occurred equally on placebo; muscle symptoms largely nocebo, not pharmacological |
| Dohlmann 2022 · Antioxidants (Basel) | RCT | contradicts | moderate | 400mg/d CoQ10 x8wk did NOT change muscle CoQ10, mitochondrial function, or myalgia in statin users; argues against CoQ10-depletion mechanism for symptoms |
| Herrett 2021 (StatinWISE) venue: Health Technol Assess · Health Technol Assess | RCT | contradicts | high | 200 N-of-1 RCTs: no overall difference in muscle symptoms between atorvastatin and placebo; statins did not cause excess myalgia |
| CTT Collaboration 2022 · Lancet | meta-analysis | mixed | high | IPD of blinded RCTs: real but small excess of muscle pain/weakness (~11 events/1000 person-yr, RR 1.03 first year); >90% of reported symptoms not statin-caused |
| Mollazadeh 2021 · J Cachexia Sarcopenia Muscle | mechanism | supports | moderate | Mechanistic review documents statin effects lowering CoQ10, inhibiting respiratory-chain complexes and triggering mitochondrial apoptosis in muscle. |
| Asping/LIFESTAT 2017 · Eur J Clin Pharmacol | RCT | mixed | moderate | 2 weeks statin: mitochondrial respiratory capacity not significantly reduced short-term; effect emerges with longer exposure, dose/time dependent |
| Mortensen/Larsen 2019 (LIFESTAT) venue: J Clin Endocrinol Metab · J Clin Endocrinol Metab | RCT | mixed | moderate | Statin decreased muscle mitochondrial respiration BUT muscle CoQ10 levels were UNALTERED, dissociating the respiration effect from CoQ10 depletion |
| El-Ganainy 2016 · Toxicology | animal | supports | low | In rats atorvastatin caused mitochondrial swelling, ATP depletion and myopathy that CoQ10 co-treatment reversed, supporting a mitochondrial mechanism. |
| Kovacic et al. 2025 · J Nutr Sci | meta-analysis | mixed | moderate | 7 RCTs n=389: modest overall reduction in SAMS pain with CoQ10 (WMD -0.96) but 3/7 trials null; heterogeneous, low-certainty benefit |
| Larsen 2013 · J Am Coll Cardiol | observational | supports | moderate | Simvastatin users had reduced muscle mitochondrial OXPHOS capacity and lower CoQ10 vs controls, linking statin to impaired respiration |
| Peyrel 2023 · PLoS One | observational | contradicts | low | In patients reporting statin muscle symptoms, drug withdrawal improved perceived but not objective muscle function, implicating a nocebo rather than true mitochondrial injury for the reported aches. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.